Quarterly ResultMay 14, 2026, 05:22 PM
PAVmed Q1 Net Loss $(6.99)M; Going Concern Doubt Raised
AI Summary
PAVmed Inc. reported a net loss attributable to common stockholders of $(6.99) million for Q1 2026, a significant decline from a net income of $17.70 million in Q1 2025. The company's operating loss also increased to $(8.04) million. Management raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows from operations. The company secured $29.91 million from Series D Preferred Stock and $15.0 million from a Senior Secured Convertible Note to support operations.
Key Highlights
- Net loss attributable to common stockholders was $(6.99) million in Q1 2026, compared to net income of $17.70 million in Q1 2025.
- Basic net loss per share was $(4.42) in Q1 2026, down from basic net income per share of $38.26 in Q1 2025.
- Operating loss increased to $(8.04) million in Q1 2026 from $(5.45) million in Q1 2025.
- Cash balance at March 31, 2026, was $6.46 million, up from $1.54 million at December 31, 2025.
- Net cash used in operating activities was $(2.62) million for Q1 2026.
- Raised $29.91 million from the issuance of Series D Preferred Stock and $15.0 million from a Senior Secured Convertible Note.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- Investment in Lucid Diagnostics had a fair value of $36.0 million as of March 31, 2026.